Chemotherapy Foundation Symposium XXVI: Innovative Cancer Therapy for Tomorrow.
نویسنده
چکیده
NEW YORK MARRIOTT MARQUIS Headquarters Hotel 1535 Broadway at 45 St., NY, NY 10036 TEL 212 398 1900 Ext 8700 or 800 843 4898 FAX 212 704 8934 On-line Reserv.: www.nymarriottmarquis.com (Grp Code caccaca) MILLENNIUM HOTEL, NEW YORK BROADWAY 145 West 44 Street at Broadway, New York, NY 10036 TEL 800 622 5569, 212 768 4400 FAX 212 789 7688 I have registered for Chemotherapy Foundation Symposium XXV Please make following reservations for me at conference rates: Chemotherapy Foundation Symposium XXV November 6-10, 2007 Registration Fees:
منابع مشابه
Chemotherapy Foundation Symposium XXIV Innovative Cancer Therapy for Tomorrow: Part 2
After nearly 50 years of research, three agents are recommended for use as the platform in colorectal cancer: 5-fluorouracil (5-FU), irinotecan (Camptosar, Pfizer), and oxaliplatin (Eloxatin, Sanofi-Synthelabo). Survival has been correlated with exposure of the patient to all three agents. Despite extending the median survival time for advanced colon cancer to more than 20 months, however, it i...
متن کاملFeasibility of high-dose iodine-131-metaiodobenzylguanidine therapy for high-risk neuroblastoma preceding myeloablative chemotherapy and hematopoietic stem cell transplantation: a study protocol
Objective(s): High-risk neuroblastoma is a childhood cancer with poorprognosis despite modern multimodality therapy. Internal radiotherapy using131I-metaiodobenzylguanidine (MIBG) is effective for treating the disease even if it isresistant to chemotherapy. The aim of this study is to evaluate the safety and efficacyof 131I-MIBG radiotherapy combined with myeloablative high-dose chemotherapyand...
متن کاملChemotherapy Foundation Symposium XIX: Innovative cancer therapy for tomorrow.
The standard therapy for acute myelogenous leukemia (AML) continues to be based on cytarabine (ara-C, DepoCyt, Enzon), typically in combination with anthracyclines such as idarubicin (Idamycin, Pfizer) or daunorubicin (Cerubidine, Bedford). Although 60% to 70% of patients achieve complete remissions (CRs), most patients relapse and ultimately die of the disease or of associated complications. T...
متن کاملThe University of California, Los Angeles/Jennifer Jones Simon Foundation Symposium on Prostate Cancer and Epithelial Cell Biology: Bringing Together Basic Scientists and Clinicians in the Fight against Advanced Prostate Cancer1
Prostate cancer is the most common solid tumor in American men and is the second most common cause of cancer deaths. Although surgery and radiation therapy are effective for the treatment of organ-confined cancer, there is no effective treatment that is currently available for patients who have metastatic disease. Antiandrogen therapy is only palliative, and chemotherapy has largely been ineffe...
متن کاملThe Effect of Group Behavioral Activation Therapy on Chemotherapy - induced Nausea and Vomiting among Women with Breast Cancer
Background and Aim: Nausea and vomiting are one of the most common and worst side effects of chemotherapy in breast cancer patient and and despite the advances in medical science, Chemotherapy Induced Nausea and Vomiting is still a challenge to control.The aim of this study was to investigate the effect of group behavioral activation therapy on Chemotherapy Induced Nausea and Vomiting among wom...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- P & T : a peer-reviewed journal for formulary management
دوره 33 12 شماره
صفحات -
تاریخ انتشار 2008